Denali Therapeutics Company
Denali Therapeutics is dedicated to defeating neurodegenerative diseases through rigorous therapeutic discovery and development.
Investors
Estimated Revenue:
$10M to $50M
Funding Status:
IPO
Industry:
Biotechnology, Genetics, Health Diagnostics, Therapeutics
Investors Number:
8
Last Funding Date:
2016
Founded Date:
2015
Headquarters:
UK
Total Funding:
347000000
Last Funding Type:
Series B
Employee Number:
251-500